##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 5 (2025)

Active hepatitis B virus vaccination in the prevention of viral reactivation in liver transplantation recipients with previous hepatitis B infection: a cohort study

Cite this as:
Swiss Med Wkly. 2025;155:4116
Published
30.05.2025

Summary

BACKGROUND AND AIM OF THE STUDY: For many years, the standard treatment following liver transplantation for hepatitis B has been a combination of hepatitis B immunoglobulin and nucleos(t)ide analogues such as entecavir and tenofovir. However, because of the high costs and logistical challenges of long-term hepatitis B immunoglobulin use, alternative approaches such as vaccination and hepatitis B immunoglobulin-free regimens are being explored. This study gathered information on a potential response (or lack thereof) and addressed the adverse events associated with active immunisation in liver transplant recipients in a Swiss cohort with hepatitis B virus (HBV)-related diseases after discontinuing hepatitis B immunoglobulin.

METHODS: Participants were recruited at the University Hospital of Bern between January 2022 and December 2023. Eligibility was restricted to liver transplant recipients with HBV-related disease who were receiving hepatitis B immunoglobulin and nucleos(t)ide analogue therapy at the time of study entry. The primary outcome was HBV relapse following hepatitis B immunoglobulin discontinuation; secondary outcomes included the response rate to active immunisation and reported adverse events. After exclusion, 18 patients were analysed. These patients, under ongoing immunosuppression and antiviral nucleos(t)ide analogue therapy, received active immunisation a minimum of 4 weeks after stopping hepatitis B immunoglobulin. Blood samples were collected at baseline and 4 weeks after vaccination, with follow-up extending for at least 12 months. Responders were defined as those with anti-HB levels of >10 IU/l. All patients received at least three vaccinations.

RESULTS: Six patients responded to the active immunisation with anti-HBs development, showing a response rate of 33.3%. No side effects or HBV recurrence were reported during the study period.

CONCLUSION: In this cohort, following liver transplantation for hepatitis B, patients who discontinued hepatitis B immunoglobulin while continuing nucleos(t)ide analogue therapy showed no relapse of hepatitis B, and a double-dose vaccination regimen yielded a modest response rate. These findings warrant further investigation into optimising vaccination strategies in this population.

References

  1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993 Dec;329(25):1842–7. doi: https://doi.org/10.1056/NEJM199312163292503
  2. Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, et al. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther. 2021 Sep;54(5):583–605. doi: https://doi.org/10.1111/apt.16374
  3. Burra P, Germani G, Adam R, Karam V, Marzano A, Lampertico P, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013 Feb;58(2):287–96. doi: https://doi.org/10.1016/j.jhep.2012.10.016
  4. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008 Jun;6(6):696–700. 10.1016/j.cgh.2008.02.055
  5. Burra P, Burroughs A, Graziadei I, et al.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol. 2016 Feb;64(2):433–85. 10.1016/j.jhep.2015.10.006
  6. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, et al.; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98. 10.1016/j.jhep.2017.03.021
  7. World Health Organization. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015.
  8. Mahmood F, Xu R, Awan MU, Song Y, Han Q, Xia X, et al. HBV Vaccines: advances and Development. Vaccines (Basel). 2023 Dec;11(12):1862. doi: https://doi.org/10.3390/vaccines11121862
  9. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002 Jan;35(1):176–81. 10.1053/jhep.2002.30278
  10. Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl. 2007 Mar;13(3):367–73. 10.1002/lt.21003
  11. Su J, Brunner L, Ates Oz E, Sacherl J, Frank G, Kerth HA, et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J Hepatol. 2023 Apr;78(4):717–30. 10.1016/j.jhep.2022.12.013
  12. Bienzle U, Günther M, Neuhaus R, et al. Immunization With an Adjuvant Hepatitis B Vaccine After Liver Transplantation for Hepatitis B-Related Disease. Hepatology. 2003 Oct;38(4):811–9. 10.1002/hep.1840380407
  13. Sánchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology. 2000 Feb;31(2):496–501. doi: https://doi.org/10.1002/hep.510310233
  14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344–9. 10.1016/j.jclinepi.2007.11.008
  15. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008 Jun;134(7):1890–9. 10.1053/j.gastro.2008.02.064
  16. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005 Apr;11(4):402–9. 10.1002/lt.20402
  17. Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, et al. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018 Sep;50(9):944–53. 10.1016/j.dld.2018.03.032
  18. Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl. 2007 Mar;13(3):367–73. 10.1002/lt.21003
  19. Sester M, Gärtner BC, Girndt M, Sester U. Vaccination of the solid organ transplant recipient. Transplant Rev (Orlando). 2008 Oct;22(4):274–84. 10.1016/j.trre.2008.07.001
  20. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013 May;31(21):2506–16. doi: https://doi.org/10.1016/j.vaccine.2012.12.012
  21. Fitzgerald B, Mac Kenzie WR, Rasmussen SA, et al. Morbidity and Mortality Weekly Report. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. MMWR Editorial and Production Staff (Serials) MMWR Editorial Board. 2018. Recommendations and Reports. 2018;67(1):1-31. Available from: https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.PDF
  22. Günther M, Neuhaus R, Bauer T, Jilg W, Holtz JA, Bienzle U. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl. 2006 Feb;12(2):316–9. 10.1002/lt.20674
  23. Yang A, Guo Z, Ren Q, Wu L, Ma Y, Hu A, et al. Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study. PLoS One. 2017 Nov;12(11):e0188190. 10.1371/journal.pone.0188190
  24. Lu SC, Jiang T, Lai W, Liu Y, Zhang J, Zeng DB, et al. Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease. J Immunol Res. 2014;2014:764234. 10.1155/2014/764234
  25. Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc. 2021 Dec;53(10):3016–21. 10.1016/j.transproceed.2021.09.038
  26. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999 Feb;179(2):489–92. 10.1086/314578
  27. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):e44–100. 10.1093/cid/cit684
  28. Stephens JW, Bernhardt JM, Director M, et al. Morbidity and Mortality Weekly Report Recommendations and Reports A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults INSIDE: Continuing Education Examination Editorial and Production Staff. 2006.
  29. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016 Jun;6(1):27251. 10.1038/srep27251
  30. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8(2):e56974. 10.1371/journal.pone.0056974
  31. Gangappa S, Kokko KE, Carlson LM, Gourley T, Newell KA, Pearson TC, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int. 2008 Apr;21(4):293–303. doi: https://doi.org/10.1111/j.1432-2277.2007.00631.x
  32. Loinaz C, de Juanes JR, Gonzalez EM, López A, Lumbreras C, Gómez R, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology. 1997;44(13):235–8.